Patients | ||||
---|---|---|---|---|
N | % | |||
PT | Tumor size | pT0, pT1 | 39 | 38 |
≥ pT2 | 61 | 60 | ||
pTx | 2 | 2 | ||
NA | 1 | 1 | ||
No surgery for PT | 20 | 16 | ||
Node invasion* | pN0 | 38 | 36 | |
pN+ | 65 | 64 | ||
Histo-prognostic grade* | 1 | 12 | 10 | |
2 | 45 | 37 | ||
3 | 63 | 51 | ||
NA | 3 | 2 | ||
PT treatment | Neo adjuvant chemotherapy | 42 | 34 | |
Adjuvant chemotherapy | 56 | 46 | ||
Adjuvant endocrine therapy | 65 | 53 | ||
Adjuvant anti HER2 therapy | 14 | 11 | ||
M | Age | median (min-max), years | 57 | (28–81) |
Time PT-M | median (min-max), months | 42 | (0–270) | |
M onset | De novo M | 23 | 19 | |
Late M | 100 | 81 | ||
Number of M sites | 1 metastatic site | 48 | 39 | |
> 1 metastatic site | 75 | 61 | ||
M sites | Liver | 74 | 60 | |
Bone | 53 | 43 | ||
Lymph node | 54 | 44 | ||
Lung/pleura | 42 | 34 | ||
Skin | 9 | 7 | ||
CNS | 6 | 5 | ||
Ovary | 3 | 2 |